<p>Acrivon Therapeutics, Inc.（納斯達克代碼：ACRV - 獲取免費報告）首席運營官 Eric Devroe 於 1 月 13 日（星期二）購買了 10,000 股該公司的股票。每股購買價格為 1.72 美元，總交易額為 17,200.00 美元。購買後，首席運營官直接持有公司 75,308 股，價值約為 129,529.76 美元。這代表其持股增加了 15.31%。此次收購已在與 SEC 的法律文件中披露，您可以通過此鏈接訪問。</p>
<p>獲取 <strong>Acrivon Therapeutics</strong> 的提醒：</p>
<h2>Acrivon Therapeutics 股票表現</h2>
<p>在週四的午盤交易中，納斯達克 ACRV 的股票上漲了 0.04 美元，達到了 1.87 美元。該公司交易了 1,214,845 股，而其平均交易量為 6,233,631 股。Acrivon Therapeutics, Inc. 的 12 個月低點為 1.05 美元，12 個月高點為 8.00 美元。該公司的市值為 5902 萬美元，市盈率為-0.88，貝塔值為 1.73。該股票的 50 日移動平均價格為 2.30 美元，200 日移動平均價格為 1.81 美元。</p>
<p>Acrivon Therapeutics（納斯達克：ACRV - 獲取免費報告）最近於 11 月 13 日發佈了季度財報。公司報告本季度每股收益為（0.47 美元），超出市場共識預期的（0.57 美元）0.10 美元。整體來看，股票分析師預計 Acrivon Therapeutics, Inc.在當前年度的每股收益為-2.49 美元。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾家券商最近對 ACRV 進行了評估。HC Wainwright 在 11 月 25 日的研究報告中重申了對 Acrivon Therapeutics 的 “買入” 評級，並給出了 19.00 美元的目標價。Wall Street Zen 在 1 月 10 日的研究報告中將 Acrivon Therapeutics 的股票評級從 “持有” 下調至 “賣出”。Piper Sandler 在 1 月 9 日的研究報告中將 Acrivon Therapeutics 的目標價從 6.00 美元上調至 8.00 美元，並給予公司 “增持” 評級。最後，Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 Acrivon Therapeutics 的 “賣出（d-）” 評級。五位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Acrivon Therapeutics 目前的平均評級為 “適度買入”，共識目標價為 11.67 美元。</p>
<p><strong>查看我們對 Acrivon Therapeutics 的最新股票分析</strong></p>
<h2>對 Acrivon Therapeutics 的對沖基金看法</h2>
<p>一些對沖基金最近買入和賣出了該公司的股票。Focus Partners Wealth 在第三季度購買了 Acrivon Therapeutics 的新股份，價值約為 36,000 美元。Algert Global LLC 在第三季度購買了 Acrivon Therapeutics 的新股份，價值約為 81,000 美元。Two Sigma Investments LP 在第三季度將其在 Acrivon Therapeutics 的持股增加了 76.2%。Two Sigma Investments LP 現在持有 319,205 股該公司的股票，價值為 578,000 美元，此前在上個季度又購買了 138,033 股。瑞銀集團（UBS Group AG）在第三季度將其在 Acrivon Therapeutics 的持股增加了 150,057.8%。瑞銀集團現在持有 683,218 股該公司的股票，價值為 1,237,000 美元，此前在上個季度又收購了 682,763 股。最後，Jane Street Group LLC 在第二季度購買了 Acrivon Therapeutics 的新股份，價值約為 371,000 美元。機構投資者持有該公司 71.62% 的股票。</p>
<h2>Acrivon Therapeutics 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Acrivon Therapeutics 納斯達克：ACRV 是一家臨牀階段的生物技術公司，專注於開發用於治療 RAS 驅動癌症的固定肽治療藥物。其專有平台旨在增強肽分子的穩定性、細胞滲透性和靶向特異性，從而使得傳統上難以用小分子藥物或生物製劑抑制的蛋白質 - 蛋白質相互作用得以干擾。</p>
<p>該公司的主要開發候選藥物是一種選擇性靶向 KRAS G12C 突變的碳氫化合物固定肽，目前正在進行早期臨牀試驗。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Acrivon Therapeutics</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行令 14330：特朗普最大的一次</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>您現在應該投資 1,000 美元於 Acrivon Therapeutics 嗎？</h2>
<p>在您考慮 Acrivon Therapeutics 之前，您需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Acrivon Therapeutics 並不在名單上。</p>
<p>雖然 Acrivon Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

ACRV

<p>Acrivon Therapeutics 首席運營官 Eric Devroe 以每股 1.72 美元的價格購買了 10,000 股公司股票，總計 17,200 美元。這次收購使他的持股增加到 75,308 股，估值約為 129,529.76 美元，標誌着他的持倉增加了 15.31%。該交易已向美國證券交易委員會（SEC）披露。Acrivon Therapeutics 的股票交易價格為 1.87 美元，市值為 5,902 萬美元。分析師對該股票的評級不一，普遍目標價為 11.67 美元</p>

<p>Acrivon Therapeutics, Inc. (NASDAQ:ACRV - Get Free Report) COO Eric Devroe bought 10,000 shares of the business's stock in a transaction dated Tuesday, January 13th. The shares were bought at an average cost of $1.72 per share, for a total transaction of $17,200.00. Following the purchase, the chief operating officer directly owned 75,308 shares in the company, valued at approximately $129,529.76. This represents a 15.31% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.</p>
<div class="lb-trans"><p>Acrivon Therapeutics, Inc.（納斯達克代碼：ACRV - 獲取免費報告）首席運營官 Eric Devroe 於 1 月 13 日（星期二）購買了 10,000 股該公司的股票。每股購買價格為 1.72 美元，總交易額為 17,200.00 美元。購買後，首席運營官直接持有公司 75,308 股，價值約為 129,529.76 美元。這代表其持股增加了 15.31%。此次收購已在與 SEC 的法律文件中披露，您可以通過此鏈接訪問。</p>
</div><p>Get <strong>Acrivon Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Acrivon Therapeutics</strong> 的提醒：</p>
</div><h2>Acrivon Therapeutics Stock Performance</h2>
<div class="lb-trans"><h2>Acrivon Therapeutics 股票表現</h2>
</div><p>Shares of NASDAQ ACRV traded up $0.04 during midday trading on Thursday, hitting $1.87. 1,214,845 shares of the company traded hands, compared to its average volume of 6,233,631. Acrivon Therapeutics, Inc. has a 12-month low of $1.05 and a 12-month high of $8.00. The firm has a market cap of $59.02 million, a P/E ratio of -0.88 and a beta of 1.73. The stock has a 50-day moving average price of $2.30 and a 200 day moving average price of $1.81.</p>
<div class="lb-trans"><p>在週四的午盤交易中，納斯達克 ACRV 的股票上漲了 0.04 美元，達到了 1.87 美元。該公司交易了 1,214,845 股，而其平均交易量為 6,233,631 股。Acrivon Therapeutics, Inc. 的 12 個月低點為 1.05 美元，12 個月高點為 8.00 美元。該公司的市值為 5902 萬美元，市盈率為-0.88，貝塔值為 1.73。該股票的 50 日移動平均價格為 2.30 美元，200 日移動平均價格為 1.81 美元。</p>
</div><p>Acrivon Therapeutics (NASDAQ:ACRV - Get Free Report) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.57) by $0.10. As a group, equities analysts expect that Acrivon Therapeutics, Inc. will post -2.49 earnings per share for the current year.</p>
<div class="lb-trans"><p>Acrivon Therapeutics（納斯達克：ACRV - 獲取免費報告）最近於 11 月 13 日發佈了季度財報。公司報告本季度每股收益為（0.47 美元），超出市場共識預期的（0.57 美元）0.10 美元。整體來看，股票分析師預計 Acrivon Therapeutics, Inc.在當前年度的每股收益為-2.49 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several brokerages recently weighed in on ACRV. HC Wainwright reaffirmed a &#34;buy&#34; rating and issued a $19.00 price target on shares of Acrivon Therapeutics in a research note on Tuesday, November 25th. Wall Street Zen downgraded shares of Acrivon Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday, January 10th. Piper Sandler lifted their price target on shares of Acrivon Therapeutics from $6.00 to $8.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, January 9th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Acrivon Therapeutics in a research note on Monday, December 29th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Acrivon Therapeutics currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $11.67.</p>
<div class="lb-trans"><p>幾家券商最近對 ACRV 進行了評估。HC Wainwright 在 11 月 25 日的研究報告中重申了對 Acrivon Therapeutics 的 “買入” 評級，並給出了 19.00 美元的目標價。Wall Street Zen 在 1 月 10 日的研究報告中將 Acrivon Therapeutics 的股票評級從 “持有” 下調至 “賣出”。Piper Sandler 在 1 月 9 日的研究報告中將 Acrivon Therapeutics 的目標價從 6.00 美元上調至 8.00 美元，並給予公司 “增持” 評級。最後，Weiss Ratings 在 12 月 29 日的研究報告中重新發布了對 Acrivon Therapeutics 的 “賣出（d-）” 評級。五位研究分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，Acrivon Therapeutics 目前的平均評級為 “適度買入”，共識目標價為 11.67 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Acrivon Therapeutics</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Acrivon Therapeutics 的最新股票分析</strong></p>
</div><h2>Hedge Funds Weigh In On Acrivon Therapeutics</h2>
<div class="lb-trans"><h2>對 Acrivon Therapeutics 的對沖基金看法</h2>
</div><p>A number of hedge funds have recently bought and sold shares of the company. Focus Partners Wealth bought a new stake in Acrivon Therapeutics during the 3rd quarter valued at about $36,000. Algert Global LLC purchased a new stake in shares of Acrivon Therapeutics during the third quarter valued at approximately $81,000. Two Sigma Investments LP grew its holdings in shares of Acrivon Therapeutics by 76.2% during the third quarter. Two Sigma Investments LP now owns 319,205 shares of the company's stock valued at $578,000 after buying an additional 138,033 shares during the last quarter. UBS Group AG increased its position in shares of Acrivon Therapeutics by 150,057.8% during the third quarter. UBS Group AG now owns 683,218 shares of the company's stock valued at $1,237,000 after acquiring an additional 682,763 shares in the last quarter. Finally, Jane Street Group LLC purchased a new position in Acrivon Therapeutics in the 2nd quarter worth approximately $371,000. Institutional investors own 71.62% of the company's stock.</p>
<div class="lb-trans"><p>一些對沖基金最近買入和賣出了該公司的股票。Focus Partners Wealth 在第三季度購買了 Acrivon Therapeutics 的新股份，價值約為 36,000 美元。Algert Global LLC 在第三季度購買了 Acrivon Therapeutics 的新股份，價值約為 81,000 美元。Two Sigma Investments LP 在第三季度將其在 Acrivon Therapeutics 的持股增加了 76.2%。Two Sigma Investments LP 現在持有 319,205 股該公司的股票，價值為 578,000 美元，此前在上個季度又購買了 138,033 股。瑞銀集團（UBS Group AG）在第三季度將其在 Acrivon Therapeutics 的持股增加了 150,057.8%。瑞銀集團現在持有 683,218 股該公司的股票，價值為 1,237,000 美元，此前在上個季度又收購了 682,763 股。最後，Jane Street Group LLC 在第二季度購買了 Acrivon Therapeutics 的新股份，價值約為 371,000 美元。機構投資者持有該公司 71.62% 的股票。</p>
</div><h2>Acrivon Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Acrivon Therapeutics 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Acrivon Therapeutics NASDAQ: ACRV is a clinical-stage biotechnology company focused on the discovery and development of stapled peptide therapeutics for the treatment of RAS-driven cancers. Its proprietary platform is designed to enhance the stability, cell permeability and target specificity of peptide molecules, enabling the disruption of protein–protein interactions that are traditionally challenging to inhibit with small-molecule drugs or biologics.</p>
<div class="lb-trans"><p>Acrivon Therapeutics 納斯達克：ACRV 是一家臨牀階段的生物技術公司，專注於開發用於治療 RAS 驅動癌症的固定肽治療藥物。其專有平台旨在增強肽分子的穩定性、細胞滲透性和靶向特異性，從而使得傳統上難以用小分子藥物或生物製劑抑制的蛋白質 - 蛋白質相互作用得以干擾。</p>
</div><p>The company's lead development candidate is a hydrocarbon-stapled peptide selectively targeting the KRAS G12C mutation, currently in early clinical trials.</p>
<div class="lb-trans"><p>該公司的主要開發候選藥物是一種選擇性靶向 KRAS G12C 突變的碳氫化合物固定肽，目前正在進行早期臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Acrivon Therapeutics</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>A U.S. “birthright” claim worth trillions - activated quietly</li>
<li>Executive Order 14330: Trump’s Biggest Yet</li>
<li>The Crash Has Already Started (Most Just Don’t See It Yet)</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Acrivon Therapeutics</li>
<li>Elon 將 SpaceX 上市！$100 的首次公開募股機會！</li>
<li>家族信託如何幫助保護您的財富</li>
<li>一項價值數萬億的美國 “出生權” 索賠 - 靜悄悄地激活</li>
<li>執行令 14330：特朗普最大的一次</li>
<li>崩盤已經開始（大多數人只是還沒看到）</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Acrivon Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>您現在應該投資 1,000 美元於 Acrivon Therapeutics 嗎？</h2>
</div><p>Before you consider Acrivon Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在您考慮 Acrivon Therapeutics 之前，您需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Acrivon Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買...而 Acrivon Therapeutics 並不在名單上。</p>
</div><p>While Acrivon Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Acrivon Therapeutics 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Acrivon Therapeutics (NASDAQ:ACRV) 的首席運營官購入了價值 17,200.00 美元的股票